These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 526937)

  • 21. Phase II trial of bisantrene in advanced epidermoid carcinoma of the head and neck.
    Forastiere AA; Crain SM; Garbino C; Tipping SJ; Perry DJ; Kasdorf H; Van Echo DA
    Cancer Treat Rep; 1984 Apr; 68(4):687-8. PubMed ID: 6713424
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II trial of 4'-epi-doxorubicin in advanced carcinoma of head and neck origin.
    Magee MJ; Howard J; Bosl GJ; Wittes RE
    Cancer Treat Rep; 1985 Jan; 69(1):125-6. PubMed ID: 3855384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck.
    Wheeler RH; Bricker LJ; Natale RB; Baker SR
    Cancer Treat Rep; 1984 Feb; 68(2):427-8. PubMed ID: 6421483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trial of weekly pyrazofurin.
    Cummings FJ; Stoller RG; Calabresi P
    Cancer Treat Rep; 1979 Aug; 63(8):1363-5. PubMed ID: 157807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.
    Edmonson JH; Frytak S; Letendre L; Kvols LK; Eagan RT
    Cancer Treat Rep; 1979; 63(11-12):2081-3. PubMed ID: 526941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of aclacinomycin-A in head and neck cancer].
    Tsukuda M
    Gan To Kagaku Ryoho; 1984 Nov; 11(11):2335-41. PubMed ID: 6594077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of mitoguazone in patients with advanced head and neck cancer.
    Thongprasert S; Bosl GJ; Geller NL; Wittes RE
    Cancer Treat Rep; 1984 Oct; 68(10):1301-2. PubMed ID: 6525604
    [No Abstract]   [Full Text] [Related]  

  • 29. [Combination therapy with S-1 and CDDP for head and neck cancer].
    Fujii M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():150-4. PubMed ID: 16897992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical experience with bleomycin--a new cytostatic agent for cancer].
    Host H; Berdal P; Brennhovd IO; Ekroll T
    Tidsskr Nor Laegeforen; 1971 Apr; 91(10):714-6 passim. PubMed ID: 5089800
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase II trial of Baker's antifol in patients with recurrent or inoperable head and neck cancer.
    Krasnow S; Green M; Perry DJ; Eisenberger MA; Johnston-Early A; Muggia F; Cohen MH
    Cancer Treat Rep; 1986 Aug; 70(8):1039-40. PubMed ID: 3524834
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
    Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
    Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
    [No Abstract]   [Full Text] [Related]  

  • 33. [Initial experiences with the new cytotoxic drug bleomycin].
    Ganzer U; Nitze HR; Ritter R
    HNO; 1971 Apr; 19(4):115-7. PubMed ID: 5581550
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy.
    Shah MK; Engstrom PF; Catalano RB; Paul AR; Bellet RE; Creech RH
    Cancer Treat Rep; 1982 Mar; 66(3):557-8. PubMed ID: 7060043
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase II trial of pyrazofurin in patients with multiple myeloma refractory to standard cytotoxic therapy.
    Lake-Lewin D; Myers J; Lee BJ; Young CW
    Cancer Treat Rep; 1979 Aug; 63(8):1403-4. PubMed ID: 476714
    [No Abstract]   [Full Text] [Related]  

  • 36. Carboplatin, an active drug in advanced head and neck cancer.
    de Andres Basauri L; Lopez Pousa A; Alba E; Sampedro F
    Cancer Treat Rep; 1986 Oct; 70(10):1173-6. PubMed ID: 3530443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of high-dose cytarabine and cisplatin in locoregional previously untreated squamous carcinoma of the head and neck: a Piedmont Oncology Association Study.
    Craig JB; Powell BL; Jackson DV; Atkins JN; Smith LR; White DR; Richards F; Capizzi RL
    Cancer Treat Rep; 1987 Feb; 71(2):151-3. PubMed ID: 3802112
    [No Abstract]   [Full Text] [Related]  

  • 38. [Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
    Tahara M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():167-71. PubMed ID: 16897996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of advanced head and neck carcinoma with synchronous irradiation and methotrexate.
    Pointon RC; Askill CS; Hunter RD; Wilkinson PM
    Cancer Treat Rep; 1981; 65 Suppl 1():145-8. PubMed ID: 7326659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II evaluation of diaziquone in recurrent head and neck cancer.
    Kish JA; Ensley J; Al-Sarraf M
    Cancer Treat Rep; 1986 May; 70(5):671-2. PubMed ID: 3708616
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.